Emcure Pharma to launch IPO in 3 months: Namita Thapar of Shark Tank fame
During the event, when asked about her recent interest in investing in startups, Namita Thapar said, “So my father is a first-gen entrepreneur, and we run Emcure Pharmaceuticals. We're going to go public in 3 months so watch out for that big IPO."
She also said that soon Emcure Pharma is going to launch a direct-to-consumer (D2C) product and mentioned that till now only doctors were our consumers but now common people will also buy the products of Emcure Pharma.
Earlier in December, Bain Capital-backed Emcure Pharmaceuticals had filed fresh preliminary papers with capital markets regulator Sebi to raise funds through an IPO.
The IPO comprises a fresh issuance of equity shares worth Rs 800 crore and an Offer of Sale (OFS) of 1.36 crore equity shares by promoters and existing shareholders, according to the draft red herring prospectus filed in December.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.
Currently, Satish Mehta holds a 41.92% stake in the company and BC Investments owns a 13.09% stake.
Proceeds of the fresh issue will be used towards payment of debt and for general corporate purposes.
The company had also filed draft IPO papers with the Sebi in August 2021. The issue comprised a fresh issue of Rs 1,100 crore, and an OFS of 1.8 crore equity shares.
Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical
